Core Viewpoint - The announcement details a significant share reduction by a major shareholder of Tuoxin Pharmaceutical, indicating a shift in ownership structure and potential implications for investor confidence [1][2]. Shareholding Changes - The controlling shareholder, Yang Xining, and his concerted action party, Yiwos Trading Co., Ltd., reduced their stake by 1,019,100 shares, representing 0.81% of the total share capital [1][2]. - Post-reduction, the combined shareholding of Yang Xining and Yiwos decreased from 28.80% to 27.99% [1]. Financial Performance - Tuoxin Pharmaceutical reported a revenue of 422 million yuan for the previous year, a decline of 49.53% year-on-year [2]. - The net profit attributable to shareholders was -19.88 million yuan, compared to a profit of 243 million yuan in the previous year [2]. - The net profit after deducting non-recurring gains and losses was -27.26 million yuan, down from 23.2 million yuan year-on-year [2]. - The net cash flow from operating activities was 103 million yuan, an increase of 280.91% year-on-year [2]. Recent Quarterly Results - In the first quarter of 2025, Tuoxin Pharmaceutical achieved a revenue of 96.99 million yuan, a decrease of 10.46% compared to the same period last year [3]. - The net profit attributable to shareholders was -3.56 million yuan, compared to a profit of 0.21 million yuan in the same quarter last year [3]. - The net cash flow from operating activities was 28.01 million yuan, a decline of 153.72% year-on-year [3]. Dividend Distribution - The board approved a profit distribution plan, proposing no cash dividends or stock bonuses for shareholders [3]. Initial Public Offering (IPO) Details - Tuoxin Pharmaceutical was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on October 27, 2021, with an initial public offering of 31.5 million shares at a price of 19.11 yuan per share [3]. - The total funds raised amounted to 602 million yuan, with a net amount of 543 million yuan after deducting issuance costs [3][4]. - The funds were intended for projects related to nucleoside series specialty raw materials, pharmaceutical intermediates, and working capital [3].
拓新药业实控人方套现3326万元 2021上市中天国富保荐